{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:45:19Z","timestamp":1789429519495,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"am","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.therap.2019.07.004","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T11:02:35Z","timestamp":1564138955000},"page":"301-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Statin-associated myasthenia: A case report and literature review"],"prefix":"10.1016","volume":"75","author":[{"given":"Val\u00e9rie","family":"Gras-Champel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e8s","family":"Masmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Batteux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe-Edouard","family":"Merle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Liabeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Masmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2019.07.004_bib0135","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2019.07.004_bib0140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.therap.2019.01.004","article-title":"Pharmacoepidemiology of statins","volume":"74","author":"Bezin","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2019.07.004_bib0145","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.therap.2016.10.004","article-title":"Investigating patient narratives posted on Internet and their informativeness level for pharmacovigilance purpose: the example of comments about statins","volume":"72","author":"Kheloufi","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2019.07.004_bib0150","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/00005792-199811000-00002","article-title":"Systemic immune reactions to HMG-CoA reductase inhibitors. Report of 4 cases and review of the literature","volume":"77","author":"Rudski","year":"1998","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.therap.2019.07.004_bib0155","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/BOR.0000000000000438","article-title":"Immune-mediated necrotizing myopathy associated with statins: history and recent developments","volume":"29","author":"Tiniakou","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.therap.2019.07.004_bib0160","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: the French method and its successive updates","volume":"71","author":"Miremont-Salam\u00e9","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2019.07.004_bib0165","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3233\/JND-140045","article-title":"The epidemiology of neuromuscular disorders: a comprehensive overview of the literature","volume":"2","author":"Deenen","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.therap.2019.07.004_bib0170","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/874680","article-title":"Myasthenia gravis: a review","author":"Jayam Trouth","year":"2012","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.therap.2019.07.004_bib0175","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.therap.2019.07.004_bib0180","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/j.1875-9114.1997.tb03085.x","article-title":"Drug-induced neuromuscular blockade and myasthenia gravis","volume":"17","author":"Barrons","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.therap.2019.07.004_bib0185","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1212\/WNL.32.10.1077","article-title":"Penicillamine-induced myasthenia gravis: effects of penicillamine on acetylcholine receptor","volume":"32","author":"Bever","year":"1982","journal-title":"Neurology"},{"key":"10.1016\/j.therap.2019.07.004_bib0190","first-page":"427","article-title":"Reversible atorvastatin-associated external ophthalmoplegia, anti-acetylcholine receptor antibodies, and ataxia","volume":"118","author":"Negevesky","year":"2000","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"key":"10.1016\/j.therap.2019.07.004_bib0195","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(02)09846-X","article-title":"Statins, fibrates, and ocular myasthenia","volume":"360","author":"Parmar","year":"2002","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.therap.2019.07.004_bib0200","doi-asserted-by":"crossref","unstructured":"Khalid R, Ibad A, Thompson PD. Statins and myasthenia gravis. Muscle Nerve 54, 2016, 509","DOI":"10.1002\/mus.25155"},{"key":"10.1016\/j.therap.2019.07.004_bib0205","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1212\/01.WNL.0000145708.03876.C3","article-title":"Statin-associated exacerbation of myasthenia gravis","volume":"63","author":"Cartwright","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.therap.2019.07.004_bib0210","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/01.md.0000209337.59874.aa","article-title":"Statin-associated myasthenia gravis: report of 4 cases and review of the literature","volume":"85","author":"Purvin","year":"2006","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.therap.2019.07.004_bib0215","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/mus.21074","article-title":"Statins may aggravate myasthenia gravis","volume":"38","author":"Oh","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.therap.2019.07.004_bib0220","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1111\/j.1468-1331.2008.02234.x","article-title":"Ptosis, diplopia and statins: an association?","volume":"15","author":"Elsais","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.therap.2019.07.004_bib0225","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1752-1947-4-61","article-title":"Statin-associated weakness in myasthenia gravis: a case report","volume":"4","author":"Keogh","year":"2010","journal-title":"J Med Case Reports"},{"key":"10.1016\/j.therap.2019.07.004_bib0230","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jocn.2013.11.009","article-title":"Statins can induce myasthenia gravis","volume":"21","author":"Gale","year":"2014","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.therap.2019.07.004_bib0235","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf J"},{"key":"10.1016\/j.therap.2019.07.004_bib0240","first-page":"256","article-title":"Statin-associated myasthenic weakness","volume":"94","author":"Pasutharnchat","year":"2011","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.therap.2019.07.004_bib0245","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0140-6736(02)07795-4","article-title":"Statins and myopathy","volume":"359","author":"Hargreaves","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2019.07.004_bib0250","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature01158","article-title":"The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease","volume":"420","author":"Youssef","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.therap.2019.07.004_bib0255","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1196\/annals.1254.032","article-title":"T cells and cytokines in the pathogenesis of acquired myasthenia gravis","volume":"998","author":"Milani","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.therap.2019.07.004_bib0260","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1468-3083.2006.01838.x","article-title":"Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review","volume":"21","author":"No\u00ebl","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595719301210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595719301210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:54:08Z","timestamp":1758567248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595719301210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0040595719301210"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2019.07.004","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin-associated myasthenia: A case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2019.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}